Who Paid My Doc
Ivy Altomare
Hematology & Oncology Durham, NC Medical Doctor
NPI 1609063254 CMS profile 299193
40 Duke Medicine Cir, Durham, NC 27710
General payments
$163,964
Research payments
$8,315
Ownership & investment interest
$0
Research they led as principal investigator
$180,934
Through program year 2024, Ivy Altomare of Durham, NC is reported in the CMS Open Payments database as having received $163,964 across 214 general payments and $8,315 in research payments paid to them. Separately, studies naming them as principal investigator received $180,934 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $580 | 1 | |
| 2022 | General | $229 | 1 | |
| 2021 | General | $4,316 | 3 | |
| 2021 | Research | $8,315 | 2 | |
| 2020 | General | $55,012 | 52 | |
| 2019 | General | $103,826 | 157 |
Beside peers
- Ivy Altomare
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Ivy Altomare were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Ivy Altomare | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $103,826 | $529 | $121–$2,516 | $163 |
| 2020 | $55,012 | $339 | $82–$2,213 | $114 |
| 2021 | $4,316 | $263 | $49–$1,965 | $132 |
| 2022 | $229 | $416 | $103–$2,395 | $149 |
| 2023 | $0 | $542 | $125–$2,646 | $160 |
| 2024 | $580 | $692 | $141–$3,008 | $164 |
| 2025 | $0 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
216 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Hematology & Oncology in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.